What has been exciting is Mundipharma's support to research the current unmet needs in patients with asthma, and to truly and openly look at models that actually improve the management of those patients to get the best outcome.

David Price, Professor of Primary Care Respiratory Medicine, Primary Care Respiratory Society UK


In respiratory, our mission is to work together with healthcare professionals to reduce the individual and societal burden of asthma – a chronic and debilitating condition affecting 30 million people in Europe.1 A better understanding of patient needs, combined with sophisticated science and technology, enables us to develop new and innovative approaches to help those affected by respiratory conditions.

Mundipharma brings more to asthma

In our quest to find better solutions in asthma, we continue to invest in research to identify and shape new ways of helping people with asthma recognise, understand and better manage their condition to lead fuller lives.

Working together with leading respiratory experts, we initiated the REALISE™ (REcognise Asthma and LInk to Symptoms and Experience) survey to uncover some of the underlying reasons for sub-optimal asthma control in Europe. The survey is the largest and most recent survey of its kind and was conducted across 11 European countries in 8,000 people with asthma aged 18-50 who use social media.2-8 REALISE™ revealed a number of psychological factors that may affect a patient’s experience of asthma, such as identity, recognition of symptoms, confidence in disease management and perceptions towards inhaler use. These insights highlight the significant yet underestimated role patient attitudes and behaviours play in asthma management.8

Finding better solutions in asthma management

The continued success and future of Mundipharma respiratory will be driven by a heightened focus on understanding and recognising differences in attitudes and behaviours, including the important role the choice of device can make to patient acceptance and adherence, and collaboration with the medical community and patient groups. Together, we can enable significant advances towards improving disease management and facilitate the development of tailored asthma management strategies, with patients being kept at the forefront.

The product range includes:

flutiform® (fluticasone propionate/ formoterol) is a combination of fluticasone propionate, an inhaled corticosteroid, and formoterol fumarate, a long-acting β2-agonist (LABA) therapy, delivered by a pressurised metered-dose inhaler (pMDI).



  1. Braman, S. The Global Burden of Asthma. Chest 2006;130:4S-12S.
  2. Demoly, P., Annunziata, K., Gubba, E., Adamek, L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012;21(123):66–74
  3. Rabe, K.F., Adachi, M., Lai, C.K., Soriano, J.B., Vermeire, P.A., Weiss, K.B., Weiss, S.T. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114(1):40–47
  4. Bellamy, D., Harris, T. Poor perceptions and expectations of asthma control: results of the International Control of Asthma Symptoms (ICAS) survey of patients and general practitioners. Prim Care Respir J 2005;14(5):252–258
  5. Partridge, M.R., Dal Negro, R.W., Olivieri, D. Understanding patients with asthma and COPD: insights from a European study. Prim Care Respir J 2011;20(3):315–323
  6. Vermeire, P.A., Rabe, K.F., Soriano, J.B., Maier, W.C. Asthma control and differences in management practices across seven European countries. Respir Med 2002;96(3):142-149
  7. Haughney, J., Barnes, G., Partridge, M., Cleland, J. The Living & Breathing Study: a study of patients' views of asthma and its treatment. Prim Care Respir J 2004;13(1):28-35
  8. Price, D.,Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.  npj Primary Care Respiratory Medicine 2014 (24), Article number: 14009; doi:10.1038/npjpcrm.2014.9; published online 12 June 2014


August 2015